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Abstract
Background: Progesterone receptor membrane component 1 (PGRMC1) is a member of a progesterone-binding 
complex implicated in female reproduction. We aimed i) to determine the natural expression of PGRMC1 in peripheral 
nucleated blood cells throughout the menstrual cycle and ii) to investigate any association between PGRMC1 levels in 
leukocytes and conditions characterized by reduced fertility.
Methods: We analyzed PGRMC1 expression in peripheral leukocytes from 15 healthy cycling women over four weeks. 
Additionally, we determined PGRMC1 levels in samples from patients with premature ovarian failure (POF) and 
polycystic ovary syndrome (PCOS) as well as in healthy postmenopausal women and male controls. The levels of 
PGRMC1 protein in nucleated peripheral blood cells were quantified by Western blot analysis.
Results: PGRMC1 levels did not vary significantly throughout the menstrual cycle. We observed a significant down-
regulation of PGRMC1 in postmenopausal women and in patients with premature ovarian failure (POF) and polycystic 
ovary syndrome (PCOS) when compared to early follicular phase of healthy women.
Conclusion: This study suggests that reduced levels of PGRMC1 in peripheral leukocytes are associated with 
perturbed ovulatory function.
Background
An important mediator of progesterone's effects is its
nuclear progesterone receptor ( P G R ) .  H o w e v e r ,  i t  h a s
recently become evident that, at least in the uterus, many
of the actions initialized by progesterone are mediated by
non-genomic progesterone receptors [1], e.g. progester-
one receptor membrane component 1 (PGRMC1; [2,3]).
PGRMC1 was first described in 1998 [4] as a putative
progesterone-binding membrane receptor of approxi-
mately 22 kDa [2]. The protein is expressed in a variety of
tissues, e.g. liver, kidney, adrenal glands, uterus and leu-
kocytes [2,5,6]. It was recently shown that PGRMC1 is
part of a membrane complex that binds progesterone
[2,3]. PGRMC1 is believed to be involved in progesterone
signaling in the reproductive system and it mediates pro-
gesterone's anti-apoptotic effects on granulosa cells
[2,5,7,8]. PGRMC1 binds to and positively regulates sev-
eral members in the microsomal cytochrome P450 family
of proteins, which are key players in intracellular sterol
metabolism and steroidogenesis [5,6,9,10]. We have
recently shown that reduced PGRMC1 levels are associ-
ated with premature ovarian failure (POF; [5]). Further-
more, a PGRMC1 missense variant identified in a patient
with POF shows perturbed interaction with the P450
member CYP7A1 [5]. Recent studies have characterized
the expression of PGRMC1 in uterine and placental tis-
sues of murine origin [8,11]. Nothing is known about the
natural variation of PGRMC1's expression throughout
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the human menstrual cycle or about the association of
PGRMC1 levels to conditions with reduced fertility.
The aim of this study was to determine the natural
expression levels of PGRMC1 in an easy accessible tissue
throughout the menstrual cycle and to assess PGRMC1
levels in conditions associated with reduced fertility and
anovulation. PGRMC1 is ubiquitously expressed and we
selected nucleated peripheral blood cells for the analysis.
Methods
Healthy women and control groups
We enrolled 15 healthy cycling women (termed healthy
females, HF) with a mean age of 27.5 ± 8.0 years, regular
menses (28.0 ± 2.2 days, range 25 - 32 days) and without
steroids or oral contraceptives during the past three
months. Their control status was evaluated by medical
history and a clinical examination. A retrospective assess-
ment was used to establish their menstrual cycle pattern
prior to inclusion, i.e. individuals were asked if they had
regular menstrual cycles and their usual cycle length (in
days) was noted. Venous blood samples were obtained
twice weekly during four consecutive weeks. Estradiol
and progesterone serum concentrations, the LH surge
and records on the first day of menstrual bleeding were
used to assign every sample to a distinct phase of a stan-
dardized 28-day menstrual cycle (table 1). Menstrual
cycle phases were divided in early follicular phase (eFP;
postmenstrual day 1-7), late follicular phase (lFP; post-
menstrual day 8 - 11), preovulatory phase (PO; LH-1 -
LH-2), early luteal phase (eLP; LH +1 - LH +5), mid-luteal
phase (mLP; LH +6 - LH +10), late luteal phase (lLP; LH
+11 - LH +14 or premenstrual days -1 - -4). If more than
one sample from the same individual was assigned to the
same cycle phase, mean values were calculated for the
individual subject. Ovulation was determined in each
subject by measuring levels of LH in urine samples
(Clearplan, Unipath, Bedford, UK). Progesterone and
estradiol were measured on Immulite 1000 (DPC, USA).
For the estradiol assay the measured interval was 73-7300
pmol/l.
Five healthy natural postmenopausal women (PM; 62.0
± 3.2 years of age) and four healthy men (HM) were
included in the study as reference groups. The PM
women were postmenopausal since 11.2 ± 3.0 years and
were without any hormone replacement therapy during
the past year. Mean FSH serum concentrations of PM
were 62.0 ± 22.0 mIU/ml. Healthy men were between 30
and 75 years old (43.0 ± 18.1 years of age).
PCOS and POF patients
Six women (mean age of 27.6 ± 6.9 years) with polycystic
ovary syndrome (PCOS) and eight patients (mean age of
35.2 ± 6.3 years) with idiopathic premature ovarian fail-
ure (POF) were included. PCOS diagnosis was defined
according to the Rotterdam criteria [12]. All three fea-
tures had to be present for diagnosis 1) oligomenorrhea
with eight or fewer menstruations in the previous 12
months or amenorrhea; 2) clinical and/or biochemical
indications of hyperandrogenism; 3) polycystic ovaries on
ultrasound examination (> 12 follicles 2 to 9 mm in diam-
eter) and/or increased ovarian volume (> 10 ml). PCOS
diagnosis also implied that no evidence of thyroid disease
(normal s-TSH), adrenocortical dysfunction (normal 17-
hydroxyprogesterone), or hyperprolactinemia (prolactin
< 30 μg/ml) was present. All six PCOS patients had bio-
chemical or clinical signs of hyperandrogenism. Mean
free androgen index was 8.4 ± 5.4 and mean FSH level
was 3.9 ± 1.4 mIU/ml. The POF group comprised three
patients with primary amenorrhea and elevated FSH (>40
mIU/ml) and five patients with secondary amenorrhea
(of which four had FSH values > 50 mIU/ml). Mean FSH
serum concentration among POF patients was 49.8 ± 33.1
mIU/ml. PCOS and POF patients were sampled prior to
any treatment of their symptoms.
Table 1: Summary of samples from healthy women (HF) included in the study
Menstrual Phasea Number of samplesb Estrogen [pmol/l]c Progesterone [nmol/l]c
Early Follicular (eFP) 15 85.4 ± 29.7 1.02 ± 0.98
Late Follicular (lFP) 15 227.2 ± 195.1 0.64 ± 0.02
Preovulatory (PO) 7 780.2 ± 228.1 0.85 ± 0.42
Early Lutael (eLP) 13 211.3 ± 169.7 6.55 ± 4.50
Midluteal (mLP) 14 267.4 ± 101.3 27.36 ± 13.05
Late Luteal (lLP) 15 205.8 ± 193.7 10.30 ± 7.98
aAssigned phase integrating hormone measurements, LH test and information about menstrual bleeding
bNumber of samples assigned to each distinctive phase
cMean ± standard deviationSchuster et al. Reproductive Biology and Endocrinology 2010, 8:58
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Ethical statement
The healthy women constitute a group of students at
Uppsala University recruited by advertisement. Post-
menopausal women, POF and PCOS patients were
referred to the gynecologists (ISP and POK), Department
of Obstetrics and Gynecology, Uppsala University Hospi-
tal. The healthy males are employed at Uppsala Univer-
sity and were interviewed and informed by JS prior to
inclusion in the study. All participants are living in Swe-
den and gave a written informed consent prior to inclu-
sion in the study. The study was approved by the Ethical
Review board at Uppsala University, Sweden.
Analysis of PGRMC1 expression
Total protein was isolated from EDTA blood samples as
follows: Erythrocytes were lyzed by mixing blood sam-
ples with lysis buffer (115 mM NH4Cl, 10 mM KHCO3,
0.1 mM EDTA), incubating on ice for 15 minutes
(repeated once) and subsequent collection of the remain-
ing peripheral nucleated cells (PNBC) by centrifugation.
Protein was extracted from the PNBC obtained using
TRIZOL (Invitrogen) following manufacturer's protocols.
Levels of PGRMC1 protein were determined by separat-
ing protein samples on a 12% SDS-PAGE (NuPage, Invit-
rogen) and subsequent transfer to PVDF Immobilon-FL
membranes (Millipore) according to manufacturer's pro-
tocols. Proteins were detected using primary α-PGRMC1
(Sigma) and α-β-actin antibodies (Abcam), respectively.
Detected proteins were visualized using IRD680- or
IRD800 -labeled secondary antibodies, respectively
(LiCor Biosciences). Western blots were analyzed using
the Odyssey infrared imaging system, determining inte-
grated intensities for each protein following the instruc-
tions manual (LiCor Bioscience). In parallel, β-actin was
measured in the same samples and used for internal nor-
malization (PGRMC1 levellane N = Integrated Inten-
sity[PGRMC1]lane N /Integrated Intensity[β-actin]lane N).
Each sample was analyzed two to four times (loading
varying amounts) and the average of the independent
measurements was used for further analysis to rule out
experimental error.
Statistical analysis
Data were analyzed using the programs Excel® (Micro-
soft®) and Minitab Statistical Software™ v13.20 (Minitab
INC). The differences between study groups were tested
for significance as follows: First, data was tested for nor-
mal distribution (Anderson-Darling and Kolmogorov-
Smirnov normality tests) and equal variance (Bartlett's
and Levene's test). The data was not normally distributed
and showed unequal variance. Differences within and
between study groups were tested with the Kruskal-Wal-
lis test and a significant p-value was obtained (p < 0.001).
Subsequently, pairwise differences were investigated
using a post hoc test (Mann-Whitney U-test).
Results
We obtained eight venous EDTA blood samples from
each of 15 healthy women during four weeks. The time
spans approximately one menstrual cycle and none of the
women were on any hormonal treatment. Serum estro-
gen and progesterone levels were measured in each sam-
ple. Both hormones showed expected and normal profiles
over the four weeks period (table 1). The hormone pro-
file, LH surge and first day of menstrual bleeding were
used to assign every sample to a distinct day of a stan-
dardized 28 day menstrual cycle (table 1). Subsequently,
we analyzed PGRMC1 protein levels in total protein
preparations derived from PNBCs by Western Blot analy-
sis (figure 1). We established expression profiles for
PGRMC1 throughout the menstrual cycle (figure 2A).
The levels of PGRMC1 were found stable across the men-
strual cycle, with a tendency to peak in the preovulatory
phase (though non-significant compared to any other
cycle phase). Interestingly, there was no correlation
between PGRMC1 levels and estradiol or progesterone
variations. We next analyzed PGRMC1 levels in blood
samples obtained from 6 patients with polycystic ovary
syndrome (PCOS) and 8 patients with premature ovarian
failure (POF). In addition, we included four healthy men
and five healthy postmenopausal women as reference
groups. The results from the PGRMC1 analyses in PCOS
and POF patients, postmenopausal subjects and healthy
males were compared to the PGRMC1 levels during the
early follicular phase (eFP) of healthy women with ovula-
tory cycles in order to obtain comparable endocrine con-
ditions. We observed a marked reduction in levels of
PGRMC1 protein in the PCOS and POF groups in com-
parison to healthy cycling women in the early follicular
phase (figure 2B). Furthermore, a similar reduction was
observed among postmenopausal women as well as in
healthy males when compared to healthy females in eFP
(p-values < 0.01; figure 2B). The lowest PGRMC1 levels
were observed in the group of postmenopausal women.
The levels were significantly reduced when compared to
healthy females and also when compared to healthy males
(p-values < 0.05; figure 2B). POF patients displayed a
broader range in PGRMC1 expression than PCOS
patients, while PGRMC1 levels in PCOS patients fell
between levels observed in postmenopausal controls and
in males.
Discussion
Progesterone receptor membrane component 1
(PGRMC1) is a membrane progesterone-binding protein
implicated in female reproduction [1,3,5,7,9,10,13-15].Schuster et al. Reproductive Biology and Endocrinology 2010, 8:58
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PGRMC1 is widely expressed also in non-reproductive
tissue and we have for the first time established PGRMC1
expression profiles in PNBC across the human menstrual
cycle. PGRMC1 expression is unchanged across the men-
strual cycle (as has been observed previously [11]) and
does not correlate with variations in progesterone levels,
suggesting that PGRMC1 and progesterone are not
directly regulating each other in PNBC. This observation
is in contrast to previous findings indicating that
PGRMC1 is negatively regulated by progesterone and
Figure 1 Detection of PGRMC1 and β-actin by Western blot analysis in total protein preparations obtained from peripheral nucleated 
blood cells (PNBC). Representative western blot pictures illustrating detection in (A) healthy cycling women (HF; distinct phases are indicated above), 
(B-D) PCOS and POF patients and control groups (PM, natural menopausal women; HM, healthy men). Total protein preparations were separated on 
a 12% SDS-PAGE, transferred to a PVDF membrane and subsequently detected using α-PGRMC1 and α-β-actin antibodies. A protein standard was 
included and the band sizes are indicated to the left. Bands corresponding to PGRMC1 (green) and β-actin (red) are indicated.
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estrogen [16,17]. Our observation may reflect different
responses to progesterone in distinct cell types.
We investigated expression levels of PGRMC1 in
patients with reduced fertility, i.e. premature ovarian fail-
ure (POF) and polycystic ovary syndrome (PCOS). The
conditions were classified as idiopathic in all patients and
none of the patients had regular menses. Interestingly,
PGRMC1 is significantly down-regulated in patients
from both the POF and the PCOS groups, supporting a
connection between PGRMC1 levels in PNBC and ovar-
ian function [11].
Our results indicate that PGRMC1 levels in PNBC are
reduced in patients with impaired or absent ovulatory
function. PGRMC1 binds and activates cytochrome P450
proteins involved in the metabolism of drugs, hormones,
lipids and the synthesis of sterols. PGRMC1's function in
leukocytes is still unclear. We could not detect the
nuclear progesterone receptor in samples from PNBC by
RT/PCR (unpublished data) and we hypothesize that
PGRMC1 could be a candidate in mediating progester-
one's effects on inflammation, coagulation and platelet
function [18-20]. In higher organisms PGRMC1 has addi-
tional binding partners, e.g. progesterone binding protein
(Prog BP) and plasminogen activator inhibitor RNA-
binding protein (PAIRBP1) of importance for cell survival
and apoptosis [6]. Most of these functions are critical for
any tissue and may be specified by the interacting down-
stream molecules that are expressed. The induction of
metabolic pathways at the cellular level mediated by
PGRMC1 is likely to be tissue specific. Despite yet
unknown downstream partners, our finding of an associ-
ation between PGRMC1 levels in PNBC and ovulatory
function may suggest an important effect for the general
reproductive fitness. It may be hypothesized that in the
absence of ovulation a systemic induction by PGRMC1 is
not initiated.
In summary, this study demonstrates that PGRMC1
levels in PNBC are strongly associated with ovulatory
function. The levels in POF and PCOS patients are signif-
icantly reduced when compared to healthy menstruating
females. The latter group shows large inter- and intrain-
dividual variations in PGRMC1 levels with a tendency for
a peak at the preovulatory phase. Further studies on
PGRMC1 expression following larger patient cohorts
over time are warranted.
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